A study of central serotoninergic activity in healthy subjects and patients with Type 2 diabetes treated by traditional one-to-one care or Group Care

Journal of Endocrinological Investigation

Volumn 33, Issue 9, 2010, Pages 624-628

  Trento, M ^a   Kucich, C ^a   Tibaldi, P ^a   Gennari, S ^a   Tedesco, S ^a   Balbo, M ^a   Arvat, E ^a   Cavallo, F ^b   Ghigo, E ^a   Porta, M ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Group Care; Hypothalamus; Pituitary adrenal axis; Serotonin; Type 2 diabetes

Indexed keywords

CITALOPRAM; CORTICOTROPIN; GLUCOSE; HYDROCORTISONE; INSULIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ORAL ANTIDIABETIC AGENT; PRASTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DIABETIC PATIENT; EVOKED RESPONSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN BLOOD LEVEL; INTERVENTION STUDY; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROLACTIN BLOOD LEVEL; SEROTONINERGIC SYSTEM; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; CENTRAL NERVOUS SYSTEM; CITALOPRAM; DEPRESSION; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; PATIENT CARE; PEER GROUP; SELF-HELP GROUPS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 78751681334     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6815     Document Type: Article

References (22)

1. Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998, 44: 851-64.
2. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry 1998, 44: 151-62.
3. Lam DD, Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. Expert Rev Mol Med 2007, 9: 1-24.
4. Trento M, Passera P, Bajardi M, et al. Lifestyle intervention by group care prevents deterioration of type 2 diabetes: a 4-year randomized controlled clinical trial. Diabetologia 2002, 45: 1231-9.
5. Trento M, Passera P, Borgo E, et al. A 5-year randomized controlled study of learning, problem solving ability and quality of life modifications in people with type 2 diabetes managed by group care. Diabetes Care 2004, 27: 670-5.
6. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352: 837-53.
7. Trento M, Passera P, Miselli V, et al. Evaluation of the locus of control in patients with type 2 diabetes after long-term management by group care. Diabetes Metab 2006, 32: 77-81.
8. Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB. The metabolic syndrome is associated with reduced central serotoninergic responsivity in healthy community workers. J Clin Endocrinol Metabol 2006, 91: 718-21.
9. Raap DK, Van de Kar LD. Selective serotonin reuptake inhibitors and neuroendocrine function. Life Sci 1999, 65: 1217-35.
10. Matthews, DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
11. The DCCT Research Group. Reliability and validity of a diabetes quality-of-life measure for the Diabetes Control and Complications Trial (DCCT). Diabetes Care 1988, 11: 725-32.
12. Mondelli V, Gianotti L, Picu A, et al. Neuroendocrine effects of citalopram infusion in anorexia nervosa. Psychoneuroendocrinology 2006, 31: 1139-48.
13. Ramage AG. Central cardiovascular regulation and 5-hydroxytryptamine receptors. Brain Res Bull 2001, 56: 425-39.
14. Liang Y, Luo S, Cincotta AH. Long-term infusion of norepinephrine plus serotonin into the ventromedial hypothalamus impairs pancreatic islet function. Metabolism 1999, 48: 1287-9.
15. Horacek J, Kuzmiakova M, Hoschl C, Andel M, Bahbonh R. The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers. Psychoneuroendocrinology 1999, 24: 785-97.
16. Rosmond R, Bouchard C, Bjorntorp P. Increased abdominal obesity in subjects with a mutation in the 5-HT(2A) receptor gene promoter. Ann NY Acad Sci 2002, 967: 571-5.
17. Bickerdike MJ, Vickers SP, Dourish CT. 5-HT2C receptor modulation and the treatment of obesity. Diabetes Obes Metab 1999, 1: 207-14
18. Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ. Low-dose citalopram as a 5-HT neuroendocrine probe. Psychopharmacology 2001, 155: 323-6.
19. Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology 2005, 178: 268-75.
20. Miyata S, Yamada N, Irano S, Tanaka S, Kamei J. Diabetes attenuates psychological stress-elicited 5-HT secretion in the prefrontal cortex but not in the amygdale of mice. Brain Res 2007, 1147: 233-9.
21. Flory JD, Manuck SB, Matthews KA, Muldoon MF. Serotoninergic function in the central nervous system is associated with daily ratings of positive mood. Psychiatry Res 2004, 129: 11-9.
22. Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev 2008, 29: 494-511.